Observational Study of HIV Infection in Participants of Seroconvert During Dapivirine Vaginal Ring Trials
A Long-Term Observational Cohort Study of HIV Infection in Participants Who Seroconvert After Enrolment in Dapivirine Vaginal Ring Trials
研究概览
研究类型
注册 (实际的)
联系人和位置
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Both microbicide and placebo recipients in IPM 027 who have become HIV infected (HIV-1 or HIV-2) while participating in IPM 027 will be offered enrolment in IPM 007 at the exit visit of IPM 027, i.e. approximately 6 weeks after identification of HIV seroconversion.
This study includes all active IPM clinical research centres that enrol participants for IPM microbicide trials.
描述
Inclusion Criteria:
- Recent HIV seroconversion during participation in IPM 027, according to the HIV testing algorithm of that trial
- Ability and willingness to provide informed consent
- Willingness to give the research centre permission to share information with the primary health care provider (PHCP), and willingness to sign approved site-specific documentation to facilitate such sharing.
Exclusion Criteria:
- Any condition that, in the opinion of the Investigator, would preclude provision of informed consent, make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
学习计划
研究是如何设计的?
设计细节
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
ARV-Treated Participants
Those participants who received dapivirine during HIV seroconversion
|
This study is observational in nature and no investigational product will be used. Groups: ARV-Treated Participants, ARV-Naive Participants |
|
ARV-Naive Participants
Those participants who received placebo during HIV seroconversion
|
This study is observational in nature and no investigational product will be used. Groups: ARV-Treated Participants, ARV-Naive Participants |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
To identify HIV drug resistant mutations following recent seroconversion in plasma and vaginal secretions and change in resistant mutations over time in participants previously exposed to an ARV-based microbicide or a placebo.
大体时间:12 months
|
The primary outcome will be assessed by viral genotype assay at baseline and at exit from the protocol, to assess the occurrence and frequency of acquiring a drug resistant HIV virus during follow-up.
|
12 months
|
合作者和调查者
调查人员
- 学习椅:Linda-Gail Bekker、Desmond Tutu HIV Centre
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.